U.S. FDA Grants Accelerated Approval to Trodelvy for the Treatment of Metastatic Urothelial Cancer

FOSTER CITY, Calif.--(BUSINESS WIRE)--Apr. 13, 2021-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval of Trodelvy (sacituzumab govitecan-hziy) for use in adult...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news